The incidence of TP53 aberration in advanced ER-positive breast cancers was ~ 20%, equivalent to that observed in primary tumours and relatively low compared to other cancer types (International Agency for Research on Cancer, IARC) database (http://p53.iarc.fr). This evidence concerns the gene TP53 and neoplasm.